symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
CYT,3.01,0.099068,163648,108353980,0,1.13-3.1,-0.02,"Cyteir Therapeutics, Inc.",USD,0001662244,US23284P1030,550241103,NASDAQ Global Select,NASDAQ,Biotechnology,https://cyteir.com,"Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.",Dr. Markus F. Renschler M.D.,Healthcare,US,46,857 285 4140,128 Spring Street,Lexington,MA,02421,,0,https://financialmodelingprep.com/image-stock/CYT.png,2021-06-18,False,False,True,False,False
